Variance of DDAH/PRMT/ADMA pathway in atrial fibrillation dogs

Biochemical and Biophysical Research Communications

Volumn 377, Issue 3, 2008, Pages 884-888

  Liu, Hongyan ^a   Qu, Xiufen ^a   Liang, Zhaoguang ^a   Chen, Weiye ^b   Xia, Wei ^a   Song, Ying ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

Asymmetric dimethylarginine; Atrial fibrillation; Dimethylarginine dimethylaminohydrolase; Endothelial dysfunction; Nitric oxide; Nitric oxide synthase; Oxidative stress; Protein arginine methyltransferase

Indexed keywords

DIMETHYLARGININASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G),N(G) DIMETHYLARGININE; NITRATE; NITRITE; PROTEIN ARGININE METHYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HEART LEFT ATRIUM; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

AMIDOHYDROLASES; ANIMALS; ARGININE; ATRIAL FIBRILLATION; DISEASE MODELS, ANIMAL; DOGS; DOWN-REGULATION; ENDOTHELIUM; FEMALE; MALE; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PROTEIN-ARGININE N-METHYLTRANSFERASE; THROMBOSIS; UP-REGULATION;

CANIS FAMILIARIS;

EID: 56049112978     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.10.080     Document Type: Article

References (32)

1. Cai H., Li Z., Goette A., Mera F., Honeycutt C., Feterik K., Wilcox J.N., Dudley Jr. S.C., Harrison D.G., and Langberg J.J. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 106 (2002) 2854-2858
2. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
3. Fickling S.A., Williams D., Vallance P., Nussey S.S., and Whitley G.S. Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy and pre-eclampsia. Lancet 342 (1993) 242-243
4. Böger R.H., Vallance P., and Cooke J.P. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. Atheroscler. Suppl. 4 (2003) 1-3
5. Cooke J.P. Does ADMA cause endothelial dysfunction?. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2032-2037
6. Pawlak M.R., Scherer C.A., Chen J., Roshon M.J., and Ruley H.E. Arginine N-methyltransferase 1 is required for early postimplantation mouse development, but cells deficient in the enzyme are viable. Mol. Cell. Biol. 20 (2000) 4859-4869
7. Leiper J.M., Santa M.J., Chubb A., MacAllister R.J., Charles I.G., Whitley G.S., and Vallance P. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem. J. 343 (1999) 209-214
8. Ngo D.T., Heresztyn T., Mishra K., Marwick T.H., and Horowitz J.D. Aortic stenosis is associated with elevated plasma levels of asymmetric dimethylarginine (ADMA). Nitric Oxide 16 (2007) 197-201
9. Cengel A., Sahinarslan A., Biberoǧlu G., Hasanoǧlu A., Tavil Y., Tulmaç M., and Ozdemir M. Asymmetrical dimethylarginine level in atrial fibrillation. Acta Cardiol. 63 (2008) 33-37
10. Xia W., Qu X.F., Yu Y., Zhang X., Feng W., and Song Y. Asymmetric dimethylarginine concentration and early recurrence of atrial fibrillation after electrical cardioversion. Pacing Clin. Electrophysiol. 31 (2008) 1036-1040
11. Chang C.M., Wu T.J., Zhou S., Doshi R.N., Lee M.H., Ohara T., Fishbein M.C., Karagueuzian H.S., Chen P.S., and Chen L.S. Nerve sprouting and sympathetic hyperinnervation in a canine model of atrial fibrillation produced by prolonged right atrial pacing. Circulation 103 (2001) 22-25
12. Böger R.H., Bode-Böger S.M., Szuba A., Tsao P.S., Chan J.R., Tangphao O., Blaschke T.F., and Cooke J.P. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98 (1998) 1842-1847
13. Zhang R.X., Li J.X., Xiong Y.Q., and Xia C.H. Determination of Asymmetric dimethylarginine in human plasma with high performance liquid chromatography. Acta Acad. Med. Jiangxi 43 (2003) 19-21
14. Chen Y., Li Y., Zhang P., Traverse J.H., Hou M., Xu X., Kimoto M., and Bache R.J. Dimethylarginine dimethylaminohydrolase and endothelial dysfunction in failing hearts. Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H2212-H2219
15. Qin J., Chen Y.-Z., and Tu Z.-G. Study of the enzyme assay of dimethylarginine dimethylaminohydrolase in rabbit kidney. Chin. Pharmacol. Bull. 19 (2003) 348-351
16. Miyazaki H., Matsuoka H., Cooke J.P., Usui M., Ueda S., Okuda S., and Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99 (1999) 1141-1146
17. Goonasekera C.D., Shah V., Rees D.D., and Dillon M.J. Vascular endothelial cell activation associated with increased plasma asymmetric dimethyl arginine in children and young adults with hypertension: a basis for atheroma?. Blood Press 9 (2000) 16-19
18. Valkonen V.P., Paiva H., Salonen J.T., Lakka T.A., Lehtimaki T., Laakso S., and Laaksonen R. Risk of acute coronary event and serum concentration of asymmetrical dimethylarginine. Lancet 358 (2001) 2127-2128
19. Saitoh M., Osanai T., Kamada T., Matsunaga T., Ishizaka H., Hanada H., and Okumura K. High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level. Heart Vessels 18 (2003) 177-182
20. Dudley S.C., Hoch N.E., McCann L.A., Honeycutt C., Diamandopoulos L., Fukai T., Harrison D.G., Dikalov S.I., and Langberg J. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and Xanthine oxidases. Circulation 112 (2005) 1266-1273
21. Sydow K., and Münzel T. ADMA and oxidative stress. Atheroscler. Suppl. 4 (2003) 41-51
22. Jia S.J., Jiang D.J., Hu C.P., Zhang X.H., Deng H.W., and Li Y.J. Lysophosphatidylcholine-induced elevation of asymmetric dimethylarginine level by the NADPH oxidase pathway in endothelial cells. Vasc. Pharmacol. 44 (2006) 143-148
23. Kim Y.M., Guzik T.J., Zhang Y.H., Zhang M.H., Kattach H., Ratnatunga C., Pillai R., Channon K.M., and Casadei B. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative Stress in human atrial fibrillation. Circ. Res. 97 (2005) 629-636
24. Shiroshita-Takeshita .A., Schram G., Lavoie J., and Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 110 (2004) 2313-2319
25. Maack C., Kartes T., Kilter H., Schafers H.-J., Nickenig G., Bohm M., and Laufs U. Oxygen free radical release in human failing myocardium is associated with increased activity of Rac1-GTPase and represents a target for statin treatment. Circulation 108 (2003) 1567-1574
26. Dayoub H., Achan V., Adimoolam S., Jacobi J., Stuehlinger M.C., Wang B.Y., Tsao P.S., Kimoto M., Vallance P., Patterson A.J., and Cooke J.P. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 108 (2003) 3042-3047
27. Leiper J., Murray-Rust J., McDonald N., and Vallance P. S-Nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc. Natl. Acad. Sci. USA 99 (2002) 13527-13532
28. Lin K.Y., Ito A., Asagami T., Tsao P.S., Adimoolam S., Kimoto M., Tsuji H., Reaven G.M., and Cooke J.P. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106 (2002) 987-992
29. Minamino T., Kitakaze M., Sato H., Asanuma H., Funaya H., Koretsune Y., and Hori M. Plasma levels of nitrite/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 3191-3195
30. Böger R.H. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "l-arginine paradox" and acts as a novel cardiovascular risk factor. J. Nutr. 134 (2004) S2842-S2847
31. Böger R.H., Bode-Böger S.M., Tsao P.S., Lin P.S., Chan J.R., and Cooke J.P. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J. Am. Coll. Cardiol. 36 (2000) 2287-2295
32. Böger R.H. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc. Res. 59 (2003) 824-833